Prop 38: Understanding California’s Immunology Research Bond

What Prop 38 would do

If approved, Prop 38 would authorize $8.4 billion in general obligation bonds to support immunology and immunotherapy research. The proceeds would be divided evenly: $4.2 billion allocated to a single nonprofit medical research institute affiliated with the University of California, and $4.2 billion disbursed as competitive grants to California public universities and nonprofit research institutions. The program would be administered with strict accountability measures, including independent audits and annual public reporting.

The initiative also imposes a policy that any licensing revenue generated from research funded under Prop 38 would contribute to the state. Specifically, 10 percent of all revenues derived from such licensing would go to the state General Fund until the bond debt is repaid, after which additional revenues would flow to the fund established by the act. A key consumer protection is that drugs developed through the program would have to be available to California patients at a price at least 20 percent below the national average, calculated excluding California.

The bond would be repaid over roughly two decades, with annual debt service estimated at $500 million to $600 million. The total long-term cost, including interest, is projected to reach about $12 billion, though supporters argue the program could offset some costs through revenue and savings in health care spending.

Who benefits and who pays

The centerpiece of Prop 38 is a nonprofit biomedical institute that would receive half of the bond proceeds. The article notes the California Institute for Immunology and Immunotherapy (CI3) as the entity meeting the specified criteria, with Gary Michelson identified as the primary funder and drafter behind the measure. CalMatters has reported that Michelson’s affiliation with the instrument and his financial backing dominate the fundraising and messaging around Prop 38.

The other half of the bond proceeds would be distributed as grants through a council that includes California public universities and nonprofit research institutions. Within the UC system, UCLA has a notable arrangement connected to the institute: UCLA would receive 7.5% of net revenue from licenses tied to the funded research and four senior UCLA officials sit on the institute’s board. The agreement includes a governance framework intended to align incentives and oversight.

Independent investigations and reporting have highlighted the institute’s early-stage status. As of September, the institute reportedly had only a handful of employees (three), far short of its planned workforce (about 90) and well short of the $200 million budget projected for personnel and construction by mid-2026. In addition, the institute’s spending so far was about $20 million, out of a contemplated $200 million in that period. These findings underscore the risk profile of channeling half the bond to a single recipient.

The measure also recognizes UC affiliation and requires that the funded work involve California-based institutions, with governance designed to ensure accountability and transparency. Nevertheless, the concentration of funds in one institute has drawn scrutiny from opponents, who argue that science benefits from broader competition and collaboration across California’s public and nonprofit research community.

Costs, revenue, and fiscal implications

The Legislative Analyst’s Office estimates that Prop 38 would raise the state’s debt burden by about $500 million to $600 million per year for roughly 20 years. The implied total cost, including interest, is about $12 billion. Supporters contend the bond can “pay for itself” by leveraging licensing revenues and state revenue sharing, while opponents point to the substantial challenges of achieving a revenue return large enough to offset the debt over time.

A critical counterpoint often cited by opponents is that public university technology transfer has historically not produced the direct, sizable revenues required to repay a state bond on a fast timeline. CalMatters emphasizes that the expected $120 billion in state revenue over the period is a high hurdle not easily achieved by university commercialization efforts.

Additional context includes the existence of broader science funding alternatives being discussed in the Legislature. California has also considered a separate $7.5 billion science bond for 2028, and some policymakers have proposed a state-funded research agency to support immunology and other fields. These options are positioned as more flexible, scalable paths that avoid locking resources to a single institute or a ballot-driven funding mechanism.

Alternatives and context

A notable alternative is the Legislature’s proposed $7.5 billion science bond for 2028, which would support a broader spectrum of science funding, not limited to a single disease area or a single recipient. In discussions around Prop 38, some lawmakers have also endorsed a state-funded research agency modeled after national bodies that fund basic and translational science through peer-reviewed processes and competitive grants. Supporters and opponents alike acknowledge that more flexible, coordinated funding mechanisms could better align research priorities with public health needs and fiscal responsibility.

Campaign finance and public perception

Campaign finance dynamics around Prop 38 reveal a pronounced disparity: supporters have raised tens of millions, while opponents’ fundraising lags far behind. Reports as of early November noted a dramatic gap, with supporters raising approximately $72 million versus opponents’ roughly $12,000, and with Michelson identified as the dominant donor. This fundraising gap is relevant to voters because it shapes perceptions of influence, messaging, and the degree of accountability around how the measure would function in practice.

In addition to donor dynamics, supporters and opponents marshal different sets of arguments. Proponents emphasize the potential to accelerate life-saving immunology research, sustain public health innovation, reduce drug costs for Californians, and strengthen California’s role as a biomedical hub. Critics stress that the proposal would lock taxpayers into long-term debt, concentrate funding in a single institute, and rely on a revenue-return model that may be unlikely to materialize in the way proponents claim. They also warn that the financing mechanism may crowd out other health priorities that would benefit from flexible budgeting.

The official voter information and independent analyses provided by agencies like the LAO and nonpartisan outlets remain essential resources for voters evaluating Prop 38’s merits against its costs and risks.

Key risks and important clarifications

A central fiscal risk is the assumption that licensing and related revenues will offset the bond costs. Critics point out that the required revenue hurdle—roughly $120 billion over the bond period—may be unattainable given the history of university technology transfer economics, where public funding often yields foundational research but does not reliably translate into state treasury gains.

Governance and transparency are also crucial. The measure specifies that the institute’s administrative costs and certain governance bodies are subject to audits and public reporting, but there are questions about how the 2 percent cap on administrative costs would apply in practice. The text specifies the cap applies to the administrative costs of the department, council, committee, and Controller, not the institute’s internal research administration. This nuance matters for readers trying to assess the true administrative burden on state finances.

Finally, the concentration of funds in a single institute raises questions about the long-term ability to sustain broad, California-wide research impact. Proponents argue that the program would deliver high-impact results, while opponents caution that a single-institute model may undercut broader collaboration and flexibility to pursue changing scientific priorities.

What to consider when deciding how to vote

If you prioritize broad, flexible investment in California science and a governance framework that emphasizes competitive, open research, you may view Prop 38 as a risky, ballot-driven approach that could constrain future policy options. If you value targeted, high-profile immunology and immunotherapy research and are persuaded by the case that the fund could drive breakthroughs in cancer, heart disease, and Alzheimer’s, Prop 38 may seem like a logical investment with strong accountability promises.

A thoughtful comparison involves weighing the bond’s total cost against the potential health and economic benefits, the likelihood of revenue offsets, and the degree to which the funding mechanism aligns with California’s broader science and health priorities. Readers should also consider the proposed alternatives—such as a larger, more flexible 2028 science bond and a state-funded research agency—as potential pathways that could deliver science policy benefits while avoiding the long-run debt commitments associated with Prop 38.

Explicit transparency note: naming the primary recipient and the big donor

To help voters evaluate transparency and governance, it is important to name the key actors involved. The California Institute for Immunology and Immunotherapy has been identified as the primary recipient of half the bond proceeds under Prop 38. Gary Michelson, a billionaire philanthropist and inventor, wrote Prop 38 and is identified as the principal funder of the campaign. CalMatters has reported that the institute’s actual staffing, expenditures, and timeline have shown significant gaps relative to its stated plans, raising questions about readiness and risk.

For completeness, it is also relevant that UCLA would participate via a 7.5 percent net-revenue sharing arrangement tied to the institute’s licensing, with four senior UCLA officials serving on the institute’s board. These governance details, together with the institute’s current staffing and spending profile, influence readers’ assessment of risk and potential return.

Ballot context and comparable proposals—such as the Legislature’s 2028 $7.5 billion science bond and proposals for a state-funded research agency—offer important context for evaluating Prop 38 against possible alternatives that might deliver broader, more adaptable research funding while maintaining fiscal discipline.

Where to find official information

For voters seeking primary sources, consult official voter information on Prop 38, including summaries from the California Secretary of State and analyses from the Legislative Analyst’s Office. These sources provide the official ballot language, fiscal impact estimates, and policy details that underpin public debate.

Useful starting points include the California Secretary of State’s voter information and the nonpartisan outlets that regularly analyze ballot propositions.

Links to official resources help ensure readers can verify figures and implications as they prepare to vote.